Why I Just Bought These 2 Under-the-Radar Stocks
Last week, I bought shares of Dexcom (NASDAQ: DXCM) and Inari Medical (NASDAQ: NARI). But while it's obvious to me that Dexcom is an incredibly successful stock, having run up almost 3,400% since its IPO 15 years ago, it still hasn't garnered a lot of investor attention.
If Dexcom is not as well known as it should be, Inari Medical is a complete unknown. The small-cap medical device maker just went public in May. Inari is focused on minimally invasive treatments for pulmonary embolism (PE) and deep vein thrombosis (DVT). The company is already profitable, and is growing revenues by 152% on a quarterly basis. And yet, Inari is under-covered in financial media, and there has been almost no hype around the stock, despite its 50% rise so far in 2020. Let's dig in to find out why investors should consider scooping up shares of these two under-the-radar stocks too.
Image source: Getty Images.
Source Fool.com
